Intravenous hydrogen nanobubbles effect on cardiac physiology and quality of life: a single blind, dose-response study

Abstract

Hydrogen nanobubbles (HNBs) showed promise for cardiovascular health and health-related quality of life (HRQoL). This study assessed intravenous HNB effects on cardiovascular parameters and HRQoL through a randomized, single-blind trial with 52 participants across six groups (control and five HNB dosages). Over 10 sessions in 5 weeks, the outcomes were measured included blood pressure, heart rate, left ventricular ejection fraction, and HRQoL via SF-36 survey. HNB administration significantly reduced systolic (144.94 to 129.88 mmHg) and diastolic (87.18 to 78.89 mmHg). Heart rate decreased slightly, and left ventricular ejection fraction increased marginally. Improvements in diastolic function, flow-mediated dilation, and HRQoL (general health, mental health, social functioning, bodily pain) were noted. Dose-dependent effects were significant at higher doses. In conclusion, HNB therapy could enhance cardiovascular function and HRQoL. Optimizing dosages and integrating comprehensive health interventions could enhance therapeutic outcomes, providing a holistic approach to managing cardiovascular health.